Insider Buying: TELA Bio, Inc. (NASDAQ:TELA) Insider Purchases 5,000 Shares of Stock

TELA Bio, Inc. (NASDAQ:TELAGet Rating) insider Ew Healthcare Partners Fund 2, purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, May 11th. The shares were acquired at an average price of $8.82 per share, with a total value of $44,100.00. Following the transaction, the insider now owns 3,395,709 shares in the company, valued at approximately $29,950,153.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

  • On Monday, May 9th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average price of $9.38 per share, with a total value of $46,900.00.
  • On Friday, May 6th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average price of $9.55 per share, with a total value of $47,750.00.
  • On Wednesday, May 4th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average price of $9.53 per share, with a total value of $47,650.00.
  • On Monday, May 2nd, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average price of $9.32 per share, with a total value of $46,600.00.
  • On Friday, April 29th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average price of $9.17 per share, with a total value of $45,850.00.
  • On Wednesday, April 27th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average cost of $9.05 per share, for a total transaction of $45,250.00.
  • On Monday, April 25th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average cost of $9.49 per share, for a total transaction of $47,450.00.
  • On Monday, April 18th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average cost of $9.80 per share, for a total transaction of $49,000.00.
  • On Thursday, April 14th, Ew Healthcare Partners Fund 2, acquired 589 shares of TELA Bio stock. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $5,890.00.
  • On Thursday, March 31st, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average cost of $11.54 per share, for a total transaction of $57,700.00.

TELA opened at $8.60 on Thursday. The company has a debt-to-equity ratio of 1.57, a quick ratio of 4.86 and a current ratio of 5.58. TELA Bio, Inc. has a 52-week low of $8.43 and a 52-week high of $16.53. The stock has a market capitalization of $125.15 million, a PE ratio of -3.76 and a beta of 1.57. The stock’s 50 day moving average price is $10.81 and its 200-day moving average price is $11.83.

TELA Bio (NASDAQ:TELAGet Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.25). TELA Bio had a negative net margin of 112.94% and a negative return on equity of 106.93%. During the same period in the prior year, the business earned ($0.56) EPS. Research analysts forecast that TELA Bio, Inc. will post -1.86 EPS for the current fiscal year.

Several research firms have recently issued reports on TELA. Zacks Investment Research raised TELA Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, April 12th. JMP Securities reissued a “buy” rating and set a $22.00 target price on shares of TELA Bio in a research note on Tuesday, March 22nd.

Several hedge funds have recently bought and sold shares of TELA. Morgan Stanley raised its stake in shares of TELA Bio by 3,256.9% in the second quarter. Morgan Stanley now owns 6,781 shares of the company’s stock worth $109,000 after purchasing an additional 6,579 shares during the last quarter. Bank of America Corp DE raised its stake in shares of TELA Bio by 16.6% in the second quarter. Bank of America Corp DE now owns 7,682 shares of the company’s stock worth $124,000 after purchasing an additional 1,093 shares during the last quarter. Susquehanna International Group LLP purchased a new stake in TELA Bio during the fourth quarter valued at $254,000. BlackRock Inc. increased its position in TELA Bio by 4.1% during the fourth quarter. BlackRock Inc. now owns 22,392 shares of the company’s stock valued at $287,000 after acquiring an additional 886 shares during the last quarter. Finally, WMS Partners LLC purchased a new stake in TELA Bio during the first quarter valued at $327,000.

About TELA Bio (Get Rating)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Featured Articles

Insider Buying and Selling by Quarter for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.